getpdf

Constitutive Expression and Inducibility of Plasminogen Activator in Mer- Glioblastoma A1235 Cell Line and in  Mer+ A8 Cells Transfected with Bacterial ada Gene

Jadranka Lončarek2 and Jasna Sorić1*


1
Faculty of Pharmacy and Biochemistry, Dept. of Biochemistry and Molecular Biology, University of Zagreb, Ante Kovačića 1, 10 000 Zagreb, Croatia

2Ruđer Bošković Institute, Dept. of Molecular Genetics, Bijenička 54, 10 000 Zagreb, Croatia

Article history:

Received October 11, 1999
Accepted January 21, 2000

Key words:

A1235 human glioblastoma, Mer phenotype, MNNG, induction, urokinase plasminogen activator

Summary:

The alkylation repair deficient (Mer- phenotype) cells produce higher levels of proteolytic enzyme plasminogen activator (PA) after treatment with alkylation agent N-methyl- -N'-nitro-N-nitrosoguanidine (MNNG). The purpose of the present study was to investigate the induction and the stabilization of urokinase plasminogen activator (upa) transcripts in Mer- A1235 and in Mer+ A8 cells which harbor bacterial ada gene, following MNNG treatment. Northern blotting experiments revealed an increased amount of upa transcripts in Mer- A1235 human glioblastoma cell line treated with 5 µM MNNG. However, no induction of upa transcript was detected in its Mer+ counterpart cells (A8 cells) following the same drug treatment. Studies with inhibitors of RNA and protein synthesis (actinomycin D and cycloheximide, respectively) indicate that the induced increase in amount of upa mRNA was due to enhanced transcription of the upa gene. Furthermore, they revealed that the turnover of the upa mRNA is relatively low (half-life > 6 h). These results demonstrate increase in transcription of upa gene in human glioblastoma Mer- cells after MNNG treatment. They suggest that induction of the upa gene might therefore be included in a cellular response to DNA damage. 

 


*Corresponding author:           This email address is being protected from spambots. You need JavaScript enabled to view it.
                                               ++385 (0)1 4856 201